Results 171 to 180 of about 53,817 (192)

HNPP: Higher-order network-based personalized PageRank for detecting critical phase in complex biological systems. [PDF]

PLoS Comput Biol
Zhong J, Gu X, Ding D, Wei Q, Niu B, Tao T, Chen P, Liu R.   +7 more
europepmc   +1 more source

TGM2-TUFM promotes acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC through p62-mediated lipophagy. [PDF]

Respir Res
Shen J, Gou L, Sun Y, Luo P, Hong S, Zhang C, Sun Y, Shen W, Fang J, Zhang Y, Li X, Ying H, Lyu Q, Zhang J, Wei T.   +14 more
europepmc   +1 more source

Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study) [PDF]

Lung Cancer, 2016
ObjectiveThe phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not progressed following four cycles of platinum-based chemotherapy ...
Fan XIA, Yi-Long Wu, Sarayut L. Geater
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study

Cancer Cell, 2021
Hai-Yan Tu, Tangfeng Lv, Shun Lu
exaly  

Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells

Bioorganic Chemistry, 2022
Chiara Riganti, Daniel Kawano, Konrad Kowalski   +2 more
exaly  

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Annals of Oncology, 2015
Fiona Blackhall, Igor N. Bondarenko, T-C Hsia   +2 more
exaly  

Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment

Annals of Oncology, 2008
Dong Ho Lee, Cheolwon Suh, D H Yoon
exaly  

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)†

Annals of Oncology, 2013
Y-L Wu, J-J Yang, J -J Yang
exaly  

First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging

Annals of Oncology, 2011
Otto S. Hoekstra, A J de Langen, J T Marcus   +2 more
exaly  

Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer

Cancer Cell, 2018
Xifeng Wu, Chao-Kai Chou, Yuanqing Ye
exaly